[CLSTR]
< Back to situations

[ORGANIZATION]

GLP-1 receptor agonists

Featured in 13 tracked stories · first seen

Situations

[ACTIVE] [HEALTH] [US] [GB] [DE]

Expanded therapeutic research and management of GLP-1 drugs

17 clusters · 118 sources · last updated

Latest: Semaglutide recognized in new ESC cardio-renal protection guidelines

Medical research continues to expand the known therapeutic potential of GLP-1 receptor agonists like semaglutide and tirzepatide. Beyond their primary uses for diabetes and obesity, these medications are being linked to

[ACTIVE] [HEALTH] [US] [BR] [GB]

GLP-1 drugs: clinical trends, safety, and market shifts

259 clusters · 931 sources · last updated

Latest: GLP-1 weight-loss drugs linked to muscle loss and serious side effects

Since mid-2026, the expansion of GLP-1 agents for obesity has been accompanied by intensified safety monitoring and evolving clinical data. Research suggests secondary benefits, including a 21% lower risk of fragility fr

[QUIET] [HEALTH] [BR] [MX] [TR]

Body image and GLP-1 medication trends in Brazil

5 clusters · 90 sources · last updated

Latest: GLP-1 weight loss medications spark clinical debate among health professionals

Health experts and regulatory bodies in Brazil are intensifying warnings regarding the use of GLP-1 receptor agonists, such as semaglutide and tirzepatide, for weight loss. While effective for obesity, a systematic revie

Also covered in